

Two Chromogranin A-Derived Peptides Induce Calcium Entry in Human Neutrophils by Calmodulin-Regulated Calcium Independent Phospholipase A₂

Dan Zhang^{1,5,8}, Peiman Shooshtarizadeh¹, Benoît-Joseph Laventie², Didier André Colin², Jean-François Chich^{1,3}, Jasmina Vidic³, Jean de Barry⁴, Sylvette Chasserot-Golaz⁴, François Delalande¹, Alain Van Dorselaer⁶, Francis Schneider⁵, Karen Helle⁷, Dominique Aunis¹, Gilles Prévost², Marie-Hélène Metz-Boutigue^{1*}

1 INSERM U575, Physiopathologie du Système Nerveux, Strasbourg, France, **2** UPRES-EA 3432, Institut de Bactériologie de la Faculté de Médecine, Université Louis Pasteur, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, **3** INRA, Virologie et Immunologie Moléculaires, Jouy-en-Josas, France, **4** Institut des Neurosciences Cellulaires et Intégratives, UMR 7168 CNRS-Université Louis Pasteur, Strasbourg, France, **5** Département de Réanimation Médicale, Hôpital de Haute-pierre, Strasbourg, France, **6** Laboratoire de spectrométrie de masse BioOrganique, IPHC-DSA, ULP, CNRS, UMR7178, Strasbourg, France, **7** Department of Biomedicine, University of Bergen, Bergen, Norway, **8** First Hospital, Chongqing University of Medical Sciences, Chongqing, China

Abstract

Background: Antimicrobial peptides derived from the natural processing of chromogranin A (CgA) are co-secreted with catecholamines upon stimulation of chromaffin cells. Since PMNs play a central role in innate immunity, we examine responses by PMNs following stimulation by two antimicrobial CgA-derived peptides.

Methodology/Principal Findings: PMNs were treated with different concentrations of CgA-derived peptides in presence of several drugs. Calcium mobilization was observed by using flow cytometry and calcium imaging experiments. Immunocytochemistry and confocal microscopy have shown the intracellular localization of the peptides. The calmodulin-binding and iPLA2 activating properties of the peptides were shown by Surface Plasmon Resonance and iPLA2 activity assays. Finally, a proteomic analysis of the material released after PMNs treatment with CgA-derived peptides was performed by using HPLC and Nano-LC MS-MS. By using flow cytometry we first observed that after 15 s, in presence of extracellular calcium, Chromofungin (CHR) or Catestatin (CAT) induce a concentration-dependent transient increase of intracellular calcium. In contrast, in absence of extra cellular calcium the peptides are unable to induce calcium depletion from the stores after 10 minutes exposure. Treatment with 2-APB (2-aminoethoxydiphenyl borate), a store operated channels (SOCs) blocker, inhibits completely the calcium entry, as shown by calcium imaging. We also showed that they activate iPLA2 as the two CaM-binding factors (W7 and CMZ) and that the two sequences can be aligned with the two CaM-binding domains reported for iPLA2. We finally analyzed by HPLC and Nano-LC MS-MS the material released by PMNs following stimulation by CHR and CAT. We characterized several factors important for inflammation and innate immunity.

Conclusions/Significance: For the first time, we demonstrate that CHR and CAT, penetrate into PMNs, inducing extracellular calcium entry by a CaM-regulated iPLA2 pathway. Our study highlights the role of two CgA-derived peptides in the active communication between neuroendocrine and immune systems.

Citation: Zhang D, Shooshtarizadeh P, Laventie B-J, Colin DA, Chich J-F, et al. (2009) Two Chromogranin A-Derived Peptides Induce Calcium Entry in Human Neutrophils by Calmodulin-Regulated Calcium Independent Phospholipase A₂. PLoS ONE 4(2): e4501. doi:10.1371/journal.pone.0004501

Editor: Mauricio Rojas, Emory University, United States of America

Received: June 11, 2008; **Accepted:** January 15, 2009; **Published:** February 19, 2009

Copyright: © 2009 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Inserm, CNRS, Université Louis Pasteur Strasbourg, The Délégation à la Recherche clinique des Hôpitaux universitaires de Strasbourg (Grant 3150), Fondation Transplantation, French ministry de la recherche et de l'enseignement supérieur, BRAHMS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: metz@neurochem.u-strasbg.fr

Introduction

Chromogranin A (CgA) is a well-studied member of the chromogranin/secretogranin family, present in secretory cells of the nervous, endocrine and immune systems [1]. CgA was the first chromogranin to be characterized as an acidic protein co-stored and co-released with the catecholamine hormones from the chromaffin cells of the adrenal medulla. The discovery that Pancreastatin, a CgA-derived peptide (bCGA_{248–293}) was able to

inhibit the glucose-evoked insulin secretion from pancreatic beta-cells [2] initiated the concept of a prohormone function for this protein [3]. Numerous endogenous cleavage products of CgA have since been identified in the intragranular matrix of chromaffin cells, resulting from the proteolytic digestion at 13 sites [4] by intragranular enzymes, such as prohormone convertases PC1/3, PC2, neuroendocrine-specific carboxypeptidase E/H, Lys and Arg-aminopeptidases [5]. Among the CGA derived fragments, several induce biological activities [1] and their *in vitro* actions

strongly suggest involvement in homeostatic processes, such as calcium and glucose metabolisms [6], cardiovascular functions [7–11], inflammatory reactions [12,13], pain relief, tissue repair [14], gastrointestinal motility [15,16] and in the first line of defence against invading microorganisms [17–19]. The possible implication of CgA and some of its derived-peptides in human diseases has also been reviewed [20,21].

We have identified a range of antimicrobial peptides deriving from the natural processing, not only of CgA but also Chromogranin B, Proenkephalin-A and Ubiquitin co-secreted with catecholamines upon stimulation of chromaffin cells from the adrenal medulla [17,18,22–25]. These new antimicrobial peptides are integrated in the concept that the adrenal medulla plays an important role in innate immunity [26]. Furthermore, when polymorphonuclear neutrophils (PMNs), known to accumulate at sites of inflammation are stimulated by lipopolysaccharide or other bacterial agents, such as Pantone-Valentine leucocidin (PVL) [27,28], these cells produce and secrete intact and processed forms of CgA, such as Vasostatin-I and -II (residues 1–76 and 1–113) [18] and Cateslytin (residues 344–358) [17,29–31], the N-terminal fragment of Catestatin (residues 344–364) [32]. In view of the established function of PMNs as central effectors cells in innate immune responses to inflammatory stimuli, it is of a great importance to understand the implications of the production and secretion of CgA-derived peptides for the regulation of PMNs responses to external stimuli.

In the present study, we have investigated the effects of two of the potent antimicrobial CgA-derived peptides on activation of PMNs release, *i.e.*: Chromofungin (CHR, bovine/human CgA_{47–66}) [24] and Catestatin (CAT, bovine CgA_{344–364}) [17]. By use of biochemical techniques, confocal microscopy, flow cytometry, calcium imaging, surface plasmon resonance and proteomic analyses, these two CgA peptides have now been demonstrated to stimulate exocytosis from PMNs by provoking a transient Ca²⁺ entry independent of release from internal stores. The mechanism by which CHR and CAT may induce Ca²⁺ influx appears to involve calmodulin (CaM) binding. The subsequent activation of the calcium-independent phospholipase A2 (iPLA2) in the complex regulation of store-operated channels (SOCs) [33–37], seemingly potentiates the release of a range of PMNs factors of importance identified by use of nanoLC-MS/MS.

Results

Since PMNs are central effectors in innate immune response to inflammatory stimuli, we investigated the effects induced by two highly conserved antimicrobial CgA derived peptides on these cells. Chromofungin (CHR, RILSILRHQNLLKELQDLAL) corresponds to the active antifungal domain CgA_{47–66} of bovine and human Vasostatin-1 CgA_{1–76} [24] while Catestatin (CAT, RSMRLSFRARGYGFRGPGQLQL) corresponds to a potent antimicrobial peptide CgA_{344–364} conserved in both cattle and man. These two peptides are not lytic for mammalian cells and display antimicrobial activities at the micromolar range [17,24].

CHR and CAT provoked Ca²⁺ entry in PMNs

In PMNs loaded with Fluo-3, a transient Ca²⁺ influx was induced by 20 μM of either CHR or CAT (20 μM) in the presence, but not in the absence, of 1 mM free extracellular Ca²⁺ (Figure 1A). Several other CgA-derived peptides (20 μM) were compared with CHR and CAT for influx of Ca²⁺. Three peptides derived from the N-terminal CgA domain failed to affect the Ca²⁺ influx (Figure 1A). These peptides were: CgA_{4–16} (NSPMNKGDTVMK), the disulfide loop CgA_{17–40}

(CIVEVISDTLSKSPMPVSKEC) and the natural peptide CgA_{65–76} (ALQGAKERTHQQ) previously reported to be without antimicrobial activities [5]. Furthermore, mixtures of peptides resulting from the tryptic digest of CHR (R, ILSILR, HQNLLK, ELQDLAL) and CAT (SSMK, LSFR, ARAYGFR, GPGPQL) were without effect on Ca²⁺ influx nor was scrambled CAT peptide (SLPRRQLPSSAGMRGGKFAYF) of any effect (Figure 1A). Hence, the complete sequences of CHR and CAT appear to be essential for the induction of the transient Ca²⁺ influx.

The inducing effects of CHR and CAT on the Ca²⁺ influx were concentration-dependent in the 5–200 μM range (Figure 1B, C). Interestingly, the simultaneous addition of CHR and CAT at equal concentrations provoked a higher Ca²⁺ increase (Figure 1C) than the sum of effects observed by separately added peptides (Figure 1B and C), suggesting that CHR and CAT may have synergic effects on the transient Ca²⁺ entry in PMNs.

An immediate increase of activated PMNs (M1/M2) was observed 15 s after the application of either CHR or CAT (Figure 2A). With different concentrations of CHR or CAT (0–200 μM), the percentage of activated PMNs was concentration dependent, being maximal at 50 μM for CHR (45%) and CAT (60%), respectively (Figure 2B).

Ca²⁺ entry evoked by CHR and CAT via Ca²⁺ selective Store Operated Calcium channels (SOCs)

Pretreatment of PMNs with the specific blocker of SOCs, 2-aminoethyl diphenylborinate (2-APB) for 2 min before addition of peptides, completely blocked the entry of extracellular Ca²⁺ by CHR or CAT (Figure 3A and 3B), suggesting that the two peptides were involved in the activation of Store Operated Calcium Entry (SOCE) through SOCs. Ca²⁺ entry in response to CHR and CAT was also compared to that induced by Arachidonic Acid (AA), acting through the Arachidonic-Regulated Channels (ARCs) (Fig 3C). The calcium influx induced by 50 μM AA was insensitive to 2-APB, while inhibited by gadolinium chloride (Gd³⁺), in marked contrast to the influx induced by CHR or CAT (Figure 3A–C). Thus, the Ca²⁺ entry induced by the two CgA-derived peptides was pharmacologically distinct from that by AA.

Finally, the specificity for divalent cation entry into PMNs loaded with Fura-2 was assessed by comparison of the peptide induced Ca²⁺ entry (traces a and b) with that of Mn²⁺ (traces c and d) at the corresponding wavelengths of excitation ($\lambda_{\text{ex}340\text{nm}}$ and $\lambda_{\text{ex}360\text{nm}}$) (Figure 4). By comparison of the traces for CAT (a, c) and CHR (b,d) there was no evidence for Mn²⁺ entry in response to either peptide, consistent with activation of SOCs selective for Ca²⁺ and non-permeable for Mn²⁺ in PMNs [38].

Calmodulin binding of CHR and CAT

The uptake of rhodamine-labeled CHR and CAT into isolated PMNs was demonstrated by confocal microscopy (Figure 5A). After 2 min incubation, the fluorescent rhodamine-labeled peptides were detected in the cytoplasm. In contrast, the control peptide, rhodamine-labeled Hippocampal Cholinergic Neurostimulating Peptide (HCNP), unable to induce Ca²⁺ influx into PMNs (not shown), was not detected in the cytoplasm, indicating a specificity for the entry of rhodamine-labeled CHR and CAT (Figure 5A).

The two cationic sequences CAT and CHR may be aligned with two Ca²⁺-dependent CaM binding motifs 1-8-14 B and 1-5-10 [39], as illustrated in Figure 5 B and previously demonstrated for binding of CHR to CaM [24,40]. Interactions between CaM, CAT and CHR were assessed by surface plasmon resonance (SPR) (Figure 5 C1), revealing that not only CHR but also CAT






Figure 1. Ca²⁺ influx evoked in human PMNs by CGA-derived peptides. For flow cytometry analysis, human PMNs (5.10⁵ cells/ml) were loaded with Fluo-3AM probe (5 μM) and its fluorescence intensity of Fluo-3 was monitored at λ_{Em}530 nm. Traces were obtained from 3000 PMNs and are averaged from triplicates at least. Peptides were added in the Ca²⁺-free EGTA buffer at t=0 and 1.1 mM CaCl₂ at t=620 s. **A**) Time course variations of the intracellular Ca²⁺ in human PMNs in response to 20 μM CAT or 20 μM CHR and compared with other CGA-derived peptides (20 μM of CgA₄₋₁₆, CgA₁₇₋₄₀ or CgA₆₅₋₇₆), tryptic digests of either 20 μM CAT, CHR or scrambled CAT. **B, C**) Time course variations of the intracellular Ca²⁺ in human PMNs in response to increasing concentrations (1–200 μM) of CHR (**B**), CAT (**C**) or a mixture of 50 μM CAT and 50 μM CHR (**C**). doi:10.1371/journal.pone.0004501.g001




Figure 2. Concentration-dependent Ca²⁺-influx after stimulation of human PMNs by CHR and CAT. **A**) Representative diagrams of flow cytometry determination of the Ca²⁺ influx in the basic (M1) and peptide-activated (M2) windows, respectively. These influxes (in black) were obtained 15 s after the addition of 50 μM CHR or 50 μM CAT at t=0 (in grey). PMNs activated by peptide-induced Ca²⁺ influx correspond to the M2 population. **B**) Flow cytometry quantification of PMNs in the M2 window in percent of the total initial population of PMNs, after 15 s exposure to increasing concentrations of CHR or CAT (1–200 μM). doi:10.1371/journal.pone.0004501.g002

specifically interacted with CaM, while scrambled CAT was inactive. In addition, CaM interacts with both CHR and CAT (Figure 5C2) when assayed by CaM-binding affinity chromatography and dot blot immunodetection of CgA in the fixed material with anti-CHR (monoclonal anti-CGA₄₇₋₆₆) [14] and anti-CAT (polyclonal anti-CGA₃₄₄₋₃₆₄) [17].

Role of iPLA₂ in the Ca²⁺ entry evoked by CHR and CAT

Previous studies have demonstrated that functional iPLA₂ is involved in activation of SOCs from different cell types [37] and that displacement of inhibitory CaM from iPLA₂ may activate iPLA₂, subsequently generating of lysophospholipids for activation of SOCs [36]. Confocal microscopy confirmed the presence of

immunoreactive iPLA₂ in PMNs (Figure 6A, right panel). The membrane localization of immunoreactive iPLA₂ could be verified after subcellular fractionation, Triton X-100 treatment and western blotting (Figure 6B, [36]). The enzymatic activity of iPLA₂ in PMNs was stimulated not only by two CaM inhibitors, *i.e.* calmidazolium (CMZ) and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W7), but also by CHR and CAT (Figure 6C). Interestingly, a comparison of CHR and CAT sequences with two CaM-binding peptides of iPLA₂ reveals marked homologies (Figure 6D). Of note, the CHR sequence may be aligned with one of the iPLA₂ CaM-binding motif (iPLA₂₆₁₈₋₆₃₅), while the CAT sequence aligns with another, *i.e.* the iPLA₂ CaM-binding motif (iPLA₂₆₉₁₋₇₀₉) [41].

CHR and CAT directly activate SOCs via iPLA₂

Two inhibitors of iPLA₂ were compared with 2-APB for effects on peptide inducing Ca²⁺ influx (Figure 6C, 7A, B). Bromoenol lactone (BEL), a specific inhibitor of iPLA₂ and bromophenacyl bromide (BPB), an inhibitor of PLA₂, abolished the transient Ca²⁺ influx induced by CHR or CAT similarly to 2-APB. In addition, the two CaM antagonists W7 and CMZ induced longer lasting rises in influx (Figure 7C, D), that were significantly suppressed by the PLA₂ inhibitors BEL and BPB and the specific SOC blocker 2-APB.

Interestingly, CMZ and some CaM inhibitory peptides may directly activate SOCs without the release of intracellular Ca²⁺ stores [42–44]. Hence, these findings indicate that CAT and CHR, being unable to evoke a Ca²⁺ mobilization from intracellular stores in absence of extracellular Ca²⁺, by their 2-APB sensitive induction of Ca²⁺ entry *via* SOCs may converge on iPLA₂ in a manner similar to the two CaM inhibitors W7 and CMZ.

Proteomic analysis of the PMNs secretions released by CHR and CAT

PMNs secretions obtained after treatment with CHR and CAT were chromatographed by HPLC (Figure 8A, B) and the isolated fractions were identified by NanoLC-MS/MS analysis (supplementary data). Factors involved in innate immunity were identified among these proteins, *i.e.* lactotransferrin, lysozyme, neutrophil gelatinase associated lipocalin, S100 calcium binding protein A8, S100 calcium binding protein A9, heat shock 70 kDa protein and leukotriene A4 hydrolase (Figure 8C and complete data in the annex with Figures S1 and S2).

CgA-derived fragments in the PMN secretions obtained after treatment with CHR and CAT were detected by western blotting, revealing traces of Vasostatin-1 and a CAT-including fragment (CgA₃₄₀₋₃₉₅) (data not shown), consistent with the previously report of several CAT-including peptides with molecular weights in the range 70–15 kDa [17]. The major fragment corresponds to CgA₃₄₀₋₃₉₅ (15–17 kDa) after stimulation of PMNs by CAT.

Discussion

The present experiments are the first to demonstrate that not only CAT but also the distinctly different sequence CHR may play




Figure 3. Ca²⁺ influx in PMNs induced by CHR, and CAT and arachidonic acid (AA). Time-lapse intracellular calcium imaging was performed on cells loaded with 1 µM Fura-2-AM and then further treated with 20 µM CHR, 20 µM CAT and 50 µM AA in Hepes-buffered Krebs medium in presence of 2.5 mM CaCl₂. **A–C) Left panels,** Representative traces showing average change in [Ca²⁺]_i (F_{340nm}/F_{380nm}) recorded in the ratio mode from individual PMNs loaded with Fura-2. The arrow indicates the time of addition of 20 µM CHR, 20 µM CAT and 50 µM AA. In separate assays (as indicated) either 100 µM 2-aminoethyl diphenylborinate (2-APB) or 1 µM gadolinium chloride (Gd³⁺) were applied 2 min before addition of peptides or AA. Traces are averaged from triplicates. **Right panels,** Summary of data in left panels, showing the maximal Ca²⁺ influx (mean ratio ± S.E.) obtained with the different conditions as indicated below bars. (n), number of PMNs used for each experiment; *, indicate significant differences (*p* < 0.05), significance for difference from effect of CHR, CAT or AA alone. doi:10.1371/journal.pone.0004501.g003

a role in Ca²⁺ signaling outside the chromaffin cells, *i.e.* serving as immunomodulators for activation of PMNs secretion.

A rapid and effective response to challenge with pathogens is essential for the survival of all living organisms. Natural cationic host defense peptides represent lead molecules that boost innate immune responses and selectively modulate pathogen-induced inflammatory responses [45]. Among the different mechanisms that have evolved to this effect, the production of a large variety of natural antimicrobial peptides has gained increasing attention.

CHR and CAT are two antimicrobial peptides derived from CgA. They are stored in secretory granules of chromaffin cells and PMNs in a larger form, which may be processed extracellularly to the mature active peptides [17,18]. In the intragranular matrix, they result to the processing of CgA by numerous enzymes such as prohormone convertases (PC1 and 2), aminopeptidases and

carboxypeptidases. In the extracellular medium, larger forms may be processed by kallikrein located at the plasmic membrane level and by circulatory proteolytic enzymes such as plasmin and thrombin [1]. In addition, some bacterial virulence factors are indeed proteolytic enzymes, *i.e.* Glu-C protease from *Staphylococcus aureus*, and might continue the natural processing of CgA to generate the CHR and CAT fragments during infections [17,18,46].

To date only CAT has been reported to act *via* a classical surface receptor, *i.e.* the nicotinic acetylcholine receptor [32]. On the other hand, several 70–80 kDa membrane binding proteins have been reported for Vasostatin-I (CgA_{1–76}) [47,48]. Furthermore, the sequences of CHR and CAT may also be aligned with the cell penetrating peptide (CPP), Penetratin, *i.e.* (Figure 9 insert), pointing the possibility for CHR and CAT, as new members of the family of CPPs [49].




Figure 4. Specificity of the Ca²⁺ entry provoked by 50 μ M CHR and 20 μ M CAT. Characterization by spectrofluorimetry of the specificity of the Ca²⁺ entry induced by 50 μ M CHR or 20 μ M CAT for comparison with peptide effects on Mn²⁺ entry. Simultaneous recordings of fluorescent intensity variations of PMNs loaded with Fura-2 in the presence of 1 mM CaCl₂ (a, b) and 0.2 mM MnCl₂ (c, d) at the corresponding wavelengths of excitation $\lambda_{\text{Ex}340 \text{ nm}}$ and $\lambda_{\text{Ex}360 \text{ nm}}$. Divalent cations and peptides were added as indicated by arrows. Recordings are representative of three experiments. doi:10.1371/journal.pone.0004501.g004

Calcium is an universal secondary messenger involved in many cellular signal transduction pathways, regulating crucial functions such as secretion, cell motility, proliferation and cell death. Increased intracellular Ca²⁺ derives mainly from two sources: internal stores releasing Ca²⁺ into the cytosol and channels in the plasma membrane that open to allow external Ca²⁺ to flow into the cell. In PMNs, calcium signaling has been reported to be involved in oxidase activation, cell degranulation and priming response to a wide variety of proinflammatory molecules [35]. The present experiments have demonstrated that the two CgA peptides, CHR and CAT, penetrate rapidly into PMNs (Figure 5A) and subsequently interact with CaM (Figure 5C) to activate iPLA₂ (Figure 6C). Displacement of CaM leads to iPLA₂ activation and production of lysophospholipids inducing the opening of SOCs [36], the entry of Ca²⁺ and the release of innate immune factors among a long list of proteins (Figure 8C and Figures S1 and S2).

The SOCE pathway remains one of the most intriguing and long lasting mysteries of Ca²⁺ signaling [43]. The main question concerns the origin of the signal [43,50]: how does depletion of the internal Ca²⁺ store activate Ca²⁺ entry through the SOC in the plasma membrane? The Calcium Influx Factor (CIF) is a specific factor produced by the cells following depletion of Ca²⁺ stores [51] and corresponds to the diffusible messenger that is produced by Ca²⁺ stores upon their depletion traveling to the plasma membrane to activate SOCs and Ca²⁺ entry [43]. The mechanism by CIF may activate SOCs with a displacement of CaM from the inactive complex with iPLA₂. The subsequent formation of lysophospholipids and the opening of SOCs, consistent with an activation of SOCs by displacement of inhibitory CAM from the inactive complex with iPLA₂ [36,37,43]. Thus, CaM inhibitors such as chemical substances and peptides, may activate SOCs by interfering with the CaM-iPLA₂ complex [36,43]. The present experiments have made evident that CHR and CAT induce a 2-APB sensitive Ca²⁺ entry without depletion of Ca²⁺ stores in a similar manner to CaM inhibitors, pointing to iPLA₂, as the most

likely target for these two peptides, once penetrated into the cytoplasm.

Of note, CAT is an inhibitory peptide controlling catecholamine release from chromaffin cells and noradrenergic neurons by an autocrine regulatory mechanism, non-competitively blocking the influx of Ca²⁺ coupled to activation of the nicotinic acetylcholine receptor, as illustrated in Figure 9, but not when triggered by membrane depolarization [32].


Several proteins involved in innate immunity (lactotransferrin, heat shock 70 kDa protein, lysosome, neutrophil gelatinase associated lipocalin, protein S100-A8, protein S100-A9 and leukotriene A-4 hydrolase) were identified by using proteomic analysis in the secretions of neutrophils stimulated by CHR and CAT (Figure 8C). In neutrophils, azurophil, specific and gelatinase granules contain host defense proteins in their luminal spaces. The extent of mobilization of the three types of granules depends on the stimulus intensity: gelatinase granules are most easily mobilized followed by specific granules and then azurophil granules.

Lactotransferrin is an iron-binding protein that is released from activated neutrophils at sites of inflammation by the three types of granules [52] and has antimicrobial, as well as anti-inflammatory properties [53]. Lactotransferrin serves as an autoregulator to retain PMNs at inflammatory sites [54] and it was able to delay spontaneous apoptosis of neutrophils [55]. The anti-inflammatory activity of lactotransferrin is due to binding and neutralization of proinflammatory molecules and its capacity to promote activation of neutrophils and macrophages [56]. Lysozyme is also released by three types of granules [52]. In addition to enzymatic lysis of bacterial cell wall, it can also kill bacteria by a non-enzymatic mechanisms [57]. Neutrophil gelatinase associated lipocalin (NGAL) was found in specific granules of neutrophils [58,59]. It is involved in the allosteric activation of matrix-metalloproteinase (MMP)-9 and protection from degradation. It may function as an effector molecule of innate immune system [58,60].

Proteins S100-A8 and A9, two Ca²⁺-binding proteins of the S100 family are secreted from neutrophils by the three types of granules as a heterodimeric complex (S100-A8/S100-A9) [61–63]. High levels of the proteins have been found in the extra-cellular milieu during inflammatory conditions [64,65]. The S100-A8/A9 heterodimer is an antimicrobial complex that exhibits cytokine-like functions in the inflammatory sites *via* activation of NF κ B and p38MAPK [66]. Hsp70, an ubiquitous family of protein chaperones that assist in folding of newly synthesized peptides and translocation of proteins across biological membranes, plays regulatory roles in signal transduction, cell cycle and apoptosis [67]. Hsp70 is known to contribute to the mechanisms of cell protection against a variety of stress and cytotoxic factors, providing an increase of cell survival [68]. Leukotriene A-4 hydrolase is released by the specific granules of neutrophils. It catalyzes the final and committed step in the biosynthesis of leukotriene B₄, a potent chemotactic agent for neutrophils, eosinophils, monocytes and T cells that play key roles in the innate immune response [69].

A considerable number of studies have demonstrated that the neuroendocrine and immune systems communicate to promote reciprocal regulation in the host. Not only may immune cells sense pathogens and secrete proteins that modify cells of the neuroendocrine system but factors secreted by the neuroendocrine system may also bring about changes in immune cell activity [26].

In addition to CAT, substance P is another neuro-immunomodulator that may inhibit nicotinic cholinergic-stimulated catecholamine release, but displays a lower potency [70]. PACAP displays numerous functions in cells of neuronal and non neuronal origin and functional VIP/PACAP receptors have been



B

Type	Peptide	Motif	Charge
1-8-14 B		(FILW) XXXXXX (FAILVW) XXXXX (FILVW)	
	CAT	RILS I LRHQL L KELQD L	1.5+
1-5-10		XXXX (FILVW) XXX (FAILV) XXXX (FILVW)	
	CHR	RSMR L SFR A RGYG F	4+




Figure 5. Interaction of CHR and CAT with calmodulin (CaM). **A**) Fluorescence confocal microscopy of PMNs after incubation during 120 s with 20 μ M rhodamine-labeled peptides (Rho-CHR or Rho-CAT). Control peptide: 20 μ M rhodamine labeled Hippocampal Cholinergic Neurostimulating Peptide (Rho-HCNP). The PMNs nuclei were labeled with Draq-5. **B**) Alignment of the CHR and CAT sequences with two CaM binding motifs 1-8-14 B and 1-5-10. The alignment has been obtained manually so that hydrophobic residues occupy invariant positions shown with boldface letters. The net positive charge is also indicated. **C**) **(1)** Interactions between CaM, CAT and CHR by Surface Plasmon Resonance (SPR) Peptides were immobilized on a CM5 Biacore chip using amine-coupling chemistry. CaM (5 μ M) was added at arrow and allowed to stabilize for 10 min. Dissociation by washing was recorded for the following 10 min. All measurements were performed at 20°C. The resulting sensorgrams were analyzed using BIAevaluation Software. **(2)** Calmodulin-Affinity Chromatography of CHR and CAT. The retained and eluted peptides were immunodetected by dot blot with anti-CHR (monoclonal anti-CgA₄₇₋₆₈) and anti-CAT (polyclonal anti-CgA₃₄₄₋₃₆₄). Wash (5th wash after adsorption of peptides).

doi:10.1371/journal.pone.0004501.g005

demonstrated on PMNs, mediating Ca²⁺- dependent pro-inflammatory activities through the activation of multiple regulatory pathways [71]. Thus, it was demonstrated that the extracellular and intracellular Ca²⁺ play key roles in PACAP mediated proinflammatory activities [72]. In addition, it has been reported

that, in contrast to the inhibitory effect of CAT, PACAP may induce an increase of Ca²⁺ entry and catecholamine release in bovine chromaffin cells by a unique pathway distinct from nAChR, VOCs and SOCs [73]. Hence, in contrast to the action of PACAP, CAT may control the proinflammatory activity *via* a




Figure 6. CHR and CAT stimulate iPLA₂ activity. **A) Fluorescence confocal microscopy of PMNs:** Left, PMNs treated only with the secondary antibody (Alexa Fluor 488-conjugated donkey anti-rabbit IgG dilution 1:2000). Right, PMNs stained with polyclonal anti-iPLA₂ as primary antibody before Alexa Fluor 488 conjugated donkey anti-rabbit IgG. **B) Western-blot analysis:** The presence of a 82 kDa protein corresponding to iPLA₂ was immunodetected in the membrane fraction obtained from PMNs. A comparable signal was obtained from the supernatant fraction of membranes treated with 0.1% Triton X-100. **C) iPLA₂ activity assay:** Stimulation of iPLA₂ activity after treatment by 20 µM CHR or 20 µM CAT for 30 min at 37°C and comparison with the effects of two CaM-binding factors (1 µM CMZ, 50 µM W7) and one iPLA₂ inhibitor (25 µM BEL). Activity of iPLA₂ is expressed as the absorbance (Abs/mg of protein) at $\lambda_{405\text{ nm}}$. Results from two similar experiments, each performed in triplicate are presented as mean \pm S.E. * $p < 0.05$, significance for difference from controls. **D) Alignment of CHR and CAT sequences with two CaM-binding peptides of iPLA₂.** CHR sequence has been aligned with the iPLA₂ CaM-binding motif aa 618 to aa 635 while the CAT sequence has been aligned with the iPLA₂ CaM-binding motif (691–709). Corresponding homologous residues are in bold and underlined fonts. doi:10.1371/journal.pone.0004501.g006

retroactive loop, inhibiting the adrenal medulla by an autocrine mechanism while enhancing PMNs secretions of a range of immunoinactive factors.

To conclude, the data reported here are important for our understanding of the role for CgA in innate immunity and for its crucial role as a mediator in the cross-talk between the neuroendocrine and immune systems. All together, the immunomodulatory activities of CHR and CAT may be important for the design of pharmacological strategies to maintain homeostasis during recruitment of PMNs in microbial and systemic infections.

Materials and Methods

Peptide synthesis

All the synthetic peptides were prepared on an Applied Biosystems 433A peptide synthesizer (Foster City, USA), using the stepwise solid-phase approach with 9-fluorenylmethoxycarbonyl (Fmoc) chemistry. Then, the synthetic peptides were purified by RP-HPLC on a Macherey Nagel Nucleosil RP 300-7C18 column (10×250 mm; particle size 7 µm and pore size 100 nm). Rhodamine fluorophore 5(6)-carboxytetramethyl rhodamine was conjugated with peptides at the N-terminal extremity, as previously described [24]. Synthetic peptides were analysed by mass spectrometry and automated Edman sequencing on an Applied Sequencing System (Applied Biosystems, Foster City, USA) [5]. MALDI mass measurements were carried out on an Ultraflex™ TOF/TOF (Bruker Daltonics, USA) to perform a rapid control of synthetic peptides according to the procedure previously reported [74].

Cells and flow cytometry measurements

Human PMNs were prepared from buffy coats purchased at the Etablissement Français du Sang – Strasbourg, France from anonymous and healthy donors from either sex. Briefly, 40 mL of a 1/3 (vol/vol) dilution of blood cells in 0.9% (wt/vol) NaCl was layered on 12 mL of 15 J Prep (Techgen International, Voisins le Bretonneux, France). After centrifugation at $800 \times g$ for 20 min, the pellet was suspended in 30 mL of 0.9% NaCl, added to 10 mL of 6% (wt/vol) dextran, and sedimented for 30 min. Thirty mL of the supernatant was centrifuged for 10 min at $800 \times g$. The pellet was suspended in HEPES buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose, 0.1 mM EGTA, 10 mM HEPES, 3 mM Tris; pH 7.3) and the contaminating erythrocytes were removed by hypotonic lysis for 45 s and subsequent washing in HEPES buffer [75]. The final suspension was adjusted to a concentration of 6.10^6 PMNs/mL and 0.1% (Wt/vol) bovine serum albumin was added to prevent non-specific leucotoxin adherence on tube walls.

To flow cytometry measurements PMNs were suspended at a concentration of 5.10^5 cells/mL in HEPES and measurements from 3000 PMNs were carried out using a FacSort® flow cytometer (Becton-Dickinson, Le Pont de Claix, France) equipped with a 15 mW argon laser tuned to 488 nm [76].

We evaluated the intracellular calcium, using flow cytometry of cells previously loaded with 5 µM Fluo-3 (Molecular Probes, New Brunswick, USA). The increase of Fluo-3 fluorescence was measured with different CgA-derived peptides in absence or after addition of 1.1 mM extracellular CaCl₂ [77]. Fluo-3 fluorescence was measured from the fluorescence light 1 (FL1: $\lambda_{Em} = 530$ nm) using Cell Quest Pro™ software (Becton-Dickinson, Le Pont de




Figure 7. Involvement of iPLA₂ in Ca²⁺ entry evoked by CHR and CAT in PMNs. A–D) Left panels: Effects of the SOC blocker (100 μM 2-APB) and inhibitors of iPLA₂ (25 μM BEL) and PLA₂ (10 μM BPB) on Ca²⁺ entry evoked by 20 μM of CHR or CAT, and two CaM antagonists (30 μM W7 and 1 μM CMZ). The representative traces show the average change in intracellular Ca²⁺ concentration (Fura-2 ratio, F₃₄₀/F₃₈₀) recorded simultaneously in a number of individual PMNs at 37°C. The following inhibitors were added: BEL (30 min), BPB (10 min) and 100 μM 2-APB (2 min) before addition of peptides or CaM antagonists (at arrows). Results are obtained from at least three independent experiments. **Right panels:** Bars represent the maximum Ca²⁺ influx (Ratio ± S.E.) in different treatments (indicated below each bar); (n) number of PMNs; * *p* < 0.05, significance for difference from peptide or CaM antagonist alone.

doi:10.1371/journal.pone.0004501.g007




Figure 8. HPLC of proteins in PMNs secretions induced by CHR and CAT and implication for innate immunity. **A, B**) Secretion from PMNs (1.10^8 cells) was induced during 30 min stimulation by **(A)** 20 μ M CHR or **(B)** 20 μ M CAT. The secreted proteins >3 kDa were purified by RP-HPLC on a Macherey Nagel reverse-phase C18 column (4 \times 250 mm; particle size 5 μ M and pore size 100 nm). Numbered peaks in the chromatograms indicate protein fractions subjected to proteomic analyses. **(C)** Proteomic identification by NanoLC-MS/MS analysis of protein fractions involved in innate immunity (protein identification probability $>93\%$). The numbered HPLC fractions correspond to the peaks of secreted protein in the chromatograms presented in A and B, respectively. doi:10.1371/journal.pone.0004501.g008

Claix, France). Data provided are the average of three independent experiments of different cell preparations. Mean variations, mainly never exceed 10% of the measured values.

Time-lapse intracellular Ca²⁺ imaging

PMNs were incubated for 30 min at 37°C in HEPES-buffered Krebs medium (130 mM NaCl, 4.5 mM KCl, 1.2 mM MgSO₄, 2.5 mM CaCl₂, 11 mM D-glucose, 10 mM HEPES, pH 7.4) with 2 μ M Fura-2-AM. Cells were then washed with HEPES-buffered Krebs medium and subsequently incubated for 20 min to allow Fura-2-AM hydrolysis. After three additional washes the cells were placed on an inverted microscope (Axiovert 35M Zeiss, Germany), superfused with Krebs solution (1 mL/min), and alternatively illuminated at 350 \pm 10 nm and 380 \pm 10 nm. The fluorescent emission was observed using a long pass filter at 510 nm. For each excitation wavelength and every 2 s an image pair was recorded using a CCD camera (ImageEMTM, Hamamatsu Photonics, Hamamatsu, Japan) and fluorescence ratio images were calculated subsequently using MetafluorTM software (Molecular Devices, Downingtown, USA).

Spectrofluorometry determination

PMNs were loaded with Fura-2 as above and washed in EGTA buffer with 1.1 mM CaCl₂ added. Continuous variations of

fluorescence intensities were recorded using a dual excitation and dual emission spectrofluorometer Deltascan (Bioritek, PTI, Chambrande, France) with slits set at 4 nm. One mL of PMNs (4.10^6 cells/mL) was added to 1 mL of the assay solution under constant stirring in a 4 ml cuve (1 cm light path) thermostated at 37°C. Wavelengths were settled at 340 nm (Ca²⁺) and 360 nm (Mn²⁺) for excitation, and 510 nm for emission. Data were expressed in arbitrary units.

Confocal microscopy analysis of rhodamine-labelled peptide loaded PMNs

PMNs (1.10^6 /mL) were incubated 2 min at room temperature (RT) with rhodamine-labelled peptides (20 μ M) in Phosphate Buffered Saline consisting of 10.5 mM KH₂PO₄, 30 mM Na₂HPO₄, 0.154 M NaCl, pH 7.4, washed and subsequently centrifuged by cytopins of 1–2.10⁵ isolated PMNs onto glass slides (300 rpm, 10 min, RT). Cytopins were fixed with 4% (v/v) paraformaldehyde in PBS at RT for 20 min, then incubated with Draq-5 (dilution 1:500, Biostatus Limited., Leicestershire, UK) for 15 min. Stained cells were monitored with a Zeiss LSM 510 laser scanning microscope (Zeiss, Iena, Germany) equipped with a Planapo oil immersion objective (\times 63, numerical aperture 1.4).




Figure 9. Model for the action of CHR and CAT on PMNs activation. Stress and infection lead to two different pathways for stimulation of PMN secretion, by release of CgA and CgA-derived peptides from the adrenal medulla, as indicated by 1a–6a (black), and by PVL leukocidin stimulation by *S. aureus* infections, as indicated by 1b–3b (grey), respectively. Abbreviated symbols: P (CHR, CAT), P' (CAT), CPP (Cell Penetrating Peptide), CaM (calmodulin), iPLA₂ (calcium independent phospholipase A₂), LysoPL (lysophospholipids); GC (Golgi complex); PVL (Panton-Valentine leukocidin), R (receptor). The stress-stimulated pathway leads to penetration of P into the cytoplasm (2a), resulting in removal of inhibitory CaM, activation of iPLA₂ to produce LysoPL (3a) and activation of Ca²⁺ influx through SOC (4a), converging on activated docking of secretory granules (5a) and subsequent release of proteins of relevance for innate immunity (6a). The negative feedback induced by P' on nicotinic cholinergic receptor of chromaffin cell is also indicated (7a). The infective route leads to activation of the putative PVL receptor coupled to opening of Ca²⁺-channels and a rise in intracellular Ca²⁺ (3b) that converges on docking of secretory granules and subsequent secretion of proteins of relevance for innate immunity (6a). Transcription of CgA in response to stress and infection is also indicated. **Insert.** The alignment of the two P sequences (CHR and CAT) with that of Penetratin (Cell penetrating peptide, CPP).

doi:10.1371/journal.pone.0004501.g009

Surface Plasmon Resonance experiments

Experiments were conducted on a Biacore 3000™ (GE Healthcare) and peptides were immobilized on a CM5 Biacore chip using amine-coupling [78]. The surface of the chip was activated for 7 min at a flow rate of 5 μL/min with a mixture of 50 mM NHS and 0.2 mM EDC. Peptides were covalently linked to the surface giving up to 2000 resonance units (RU). Ethanolamine (1M, pH8.5) was injected for 7 min to block the remaining activated groups. 5 μM CaM (Sigma, St. Louis, MO, USA) addition was performed at an injection flow of 20 μL/min in 50 mM NaCl, 2 mM CaCl₂, 20 mM Tris pH6.5 until stabilization was reached (10 min). Dissociation was registered for 10 min after the end of injections. All measurements were performed at 20°C. Sensorgrams were analyzed by using BIAevaluation Software.

Calmodulin-Affinity Chromatography and dotblot immunodetection

CHR and CAT were prepared in buffer A (50 mM NaCl, 2 mM CaCl₂, 50 mM Tris-HCl, pH 7.5) and loaded on 0.1 ml CaM-Sepharose 4B column (GE healthcare, Buckinghamshire, United Kingdom) with molar ratio 10:1. The mixtures were incubated at room temperature for 1 h. Afterwards, the column was washed (x5) with 1 mL of buffer A, and (x3) 0.1 mL buffer B (50 mM NaCl and 2 mM EGTA, 50 mM Tris-HCl, pH 7.5) were used to elute the CaM binding peptides. The elutions were analyzed by dotblot onto PVDF membrane with pore 0.2 μM (Millepore, Billerica, MA, USA) with specific antibodies anti-CHR (monoclonal anti-CGA_{47–68} (dilution 1:5,000) and anti-CAT (anti-CGA_{344–364} (dilution 1:20,000) [17,24]. Immunoreactivity signals

were developed using goat anti-mouse IgG conjugated to peroxidase (dilution 1:400,000, Jackson ImmunoResearch laboratories, Baltimore Pike, USA).

Immunocytochemistry of iPLA₂ in PMNs

Cytospins were prepared by centrifugation of $1\text{--}2 \cdot 10^5$ isolated PMNs onto glass slides (300 rpm, 10 min), then fixed with 4% (v/v) paraformaldehyde in PBS, at RT for 20 min, permeabilized with PBS containing 1% (v/v) Triton X-100 (Sigma, St. Louis, USA) at RT for 30 min, and blocked by incubation in PBS containing 0.25% (w/v) bovine serum albumin. Subsequently, cytospins were incubated with primary antibodies anti-iPLA₂ polyclonal antibody (dilution 1:100, Cayman chemical, Ann Arbor, USA) for 1 h at 37°C. Cytospins were washed with PBS, then incubated with secondary antibodies Alexa 488-conjugated donkey anti-rabbit IgG (dilution 1:2000, Molecular Probes, Carlsbad, USA) during 45 min at 37°C, finally incubated with Draq-5 (dilution 1:500) for 15 min. Immunofluorescence staining was monitored with a Zeiss LSM 510 laser scanning microscope equipped with a Planapo oil immersion objective ($\times 63$, numerical aperture 1.4).

Detection of iPLA₂ in PMNs and iPLA₂ activity assay

Subcellular fractionation of PMNs. PMNs ($5 \cdot 10^7$ /mL) were sonicated (10 W) in the absence or presence of 1% (v/v) Triton X-100, in the buffer 1 mM phenylmethylsulphonyl fluoride, 1 mM EDTA, 50 mM Tris-HCl pH 7.5 for 3 times of 10 s with 15 s break between cycles, then spun down at $10,000 \times g$ for 15 min at 4°C. The pellet containing membranes was collected and the supernatant was further centrifuged at $100,000 \times g$ for 60 min at 4°C [44]. The amount of proteins contained in membrane and cytoplasm fractions was determined by Bradford method, and both preparations were stored at -20°C for later use.

Gel electrophoresis and Western-blot analysis of iPLA₂ in PMNs. Fifty μg proteins of each sample were separated on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis SDS-PAGE gradient gels (SDS-PAGE) and electrotransferred onto polyvinylidene difluorene membranes (GE Healthcare Bioscience). iPLA₂ were detected with a polyclonal anti-iPLA₂ (dilution 1:500, Cayman Chemicals, Ann Arbor, MI, USA), and signal was developed using goat anti-rabbit IgG conjugated to peroxidase (dilution 1:50,000, Jackson ImmunoResearch Laboratories, Baltimore Pike, USA) to determine immunoreactivity [79].

iPLA₂ activity assay. PMNs ($3 \cdot 10^8$) were collected, sonicated 3 times for 10 s with a 15 s break between cycles, and centrifuged at $15,000 \times g$ for 20 min at 4°C. The supernatant was removed and kept on ice. After determination of the protein concentration (Bradford assay), iPLA₂ activity measurement was obtained in presence of different peptide concentrations using the cPLA₂ assay kit, according to the modified method previously reported (cPLA₂ assay kit, Caymen chemical), [36]. Results were from two similar experiments, each performed in triplicates.

Characterization of secretions obtained after stimulation of PMNs by CHR and CAT

Stimulation and purification. PMNs secretory products were obtained after stimulation of $1 \cdot 10^8$ PMNs with 20 μM CHR or 20 μM CAT in EGTA buffer for 20 min. PMNs were centrifuged at $800 \times g$ for 10 min at 4°C and the supernatant was recovered. Desalting and elimination of low molecular weights protein were achieved by centrifugation with a molecular cut-off 3 kDa Centricon (Pall, New York, USA), then the material was stored at -20°C for further analyses.

PMNs secretions induced by CHR and CAT were purified using a DIONEX Dual Gradient system (Dionex, Sunnyvale, USA) and a Nucleosil RP300-5C18 column (4×250 mm, 5 μm particle size, 300-Å porosity; Macherey-Nagel, Hoerd, France). Absorbance was monitored at 214 nm, and the solvent system consisted of 0.1% (v/v) trifluoroacetic acid in water (solvent A) and 0.1% (v/v) trifluoroacetic acid in 70% (v/v) acetonitrile-water (solvent B with a flow rate of 1 mL/min. Gradient was indicated on chromatograms and fractions of 700 μL were collected.

Mass spectrometry analysis. The cysteine residues from the RP-HPLC fractions were reduced by 50 μL of 10 mM dithiothreitol at 57°C and alkylated by 50 μL of 55 mM iodoacetamide. The proteins were digested with 40 μL of 12.5 ng/ μL of modified porcine trypsin (Promega, Madison, WI, USA) in 25 mM NH_4HCO_3 at 37°C for 14 h.

The generated peptides were analyzed directly by NanoLC-MS/MS on an Agilent 1100 Series HPLC-Chip/MS system (Agilent Technologies, Palo Alto, USA) coupled to an HCT Ultra ion trap (Bruker Daltonics, Bremen, Germany). The chip contained a Zorbax 300SB-C18 (43 mm \times 75 μm , with a 5 μm particle size) column and a Zorbax 300SB-C18 (40 nL, 5 μm) enrichment column. The solvent system consisted of 2% (v/v) acetonitrile, 0.1% (v/v) formic acid in water (solvent A) and 2% (v/v) water, 0.1% formic acid in acetonitrile (solvent B). The sample was loaded into the enrichment column at a flow rate set to 3.75 $\mu\text{L}/\text{min}$ with solvent A. Elution was performed at a flow rate of 300 nL/min with a 8–40% linear gradient (solvent B) over 12 min and followed by a 70% stage (solvent B) over 5 min before the reconditioning of the column at 92% of solvent A. The complete system was fully controlled by ChemStation Rev. B.01.03 (Agilent Technologies).

All the analyses were performed using an HCT+ ion trap (Bruker Daltonics, Bremen Germany). The peptides were ionised by positive electrospray and fragmented by CID. The trap was externally calibrated with tuning mix for LC/MSD ion trap G2431A (Agilent Technologies). The voltage applied to the capillary cap was optimized to -1750 V. The MS scanning was performed in the standard enhanced resolution mode at a scan rate of 8.100 m/z per second. The mass range was 250 to 2500 m/z. The Ion Charge Control was 100000 and the maximum accumulation time was 200 ms. A total of 4 scans were averaged to obtain a MS spectrum and the rolling average was 2.

For tandem MS experiments, the system was operated with automatic switching between MS and MS/MS modes. The 3 most abundant peptides with an isolation width of 4 m/z, preferring doubly charged ions (absolute threshold of 2000 and a relative of 5%) were selected on each MS spectrum for further isolation and fragmentation. Ions were excluded after 2 spectra and released after 1 min.

Smart Parameters Setting was used for selected precursor ions. The MS/MS scanning was performed in the ultrascan resolution mode at a scan rate of 26.000 m/z per second. The mass range was 50 to 2800 m/z. The Ion Charge Control was 300000. A total of 6 scans were averaged to obtain a MS/MS spectrum. The values 30% and 200% give a start and end for fragmentation relative to the fragmentation amplitude selected (1.5 V).

The complete system was fully controlled by EsquireControl 6.1 Build 90 (Bruker Daltonics) software. Mass data collected during analysis were processed, converted into .mgf files using DataAnalysis 3.4 Build 179 (Bruker Daltonics) software. The standard parameters were used.

The smoothing algorithm was Savitzky Golay with a smoothing width of 0.2 m/z in 1 cycle. 250 compounds were selected with a threshold of 60000. The algorithm “Accu Mass” was used.

The MS and the MS/MS data were searched using a local Mascot server (version MASCOT 2. 2.0, MatrixScience, UK). Searches were performed with a mass tolerance of 200 ppm in MS mode and 0.3 Da in MS/MS mode and with the following parameters: trypsin specificity, one missed cleavage, cysteine carbamidomethylation and methionine oxidation (and protein amino-terminal acetylation) as variable modifications, trap fragmentation, without constraining protein molecular weight or isoelectric point and without any taxonomic restriction.

To minimize false positive identifications, the results were subjected to very stringent filtering criteria. For the identification of a protein with two peptides or more, at least two unique peptides had to a Mascot ion score above 20. In the case of single peptide hits, the score of the unique peptide must be greater than the 52. For the estimation of the false positive rate, a target-decoy database search was performed [80]. In this approach, peptides are matched against a database consisting of the native protein sequences found in the database (target) and of the sequence-reversed entries (decoy). The evaluations were performed using the peptide validation software Scaffold (Proteome Software, Portland, USA). This strategy was used to obtain a final catalogue of proteins with an estimated false positive rate below 1%.

Drugs

Bromo-enol Lactone (BEL), Thapsigargin (TG), Calmidazolium (CMZ), Bromophenacyl bromide (BPB), 2-Aminoethyl diphenylborinate (2-APB), N-6-aminohexyl-5-chloro-1-naphthalenesulfonamide (W7), Arachidonic acid (AA) and Rhodamine fluorophore, 5(6)-carboxytetramethyl rhodamine were purchased from Sigma (St. Louis, MO, USA).

References

- Helle KB, Corti A, Metz-Boutigue MH, Tota B (2007) The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. *Cell Mol Life Sci* 64: 2863–2886.
- Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, et al. (1986) Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. *Nature* 324: 476–478.
- Eiden LE (1987) Is chromogranin a prohormone? *Nature* 325: 301.
- Seidah NG, Chretien M (1999) Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. *Brain Res* 848: 45–62.
- Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D (1993) Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. *Eur J Biochem* 217: 247–257.
- Koetslag JH, Saunders PT, Wessels JA (1999) The chromogranins and the counter-regulatory hormones: do they make homeostatic sense? *J Physiol* 517 (Pt 3): 643–649.
- Aardal S, Helle KB (1992) The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. *Regul Pept* 41: 9–18.
- Brekke JF, Osol GJ, Helle KB (2002) N-terminal chromogranin-derived peptides as dilators of bovine coronary resistance arteries. *Regul Pept* 105: 93–100.
- Cerra MC, Gallo MP, Angelone T, Quintieri AM, Pulera E, et al. (2008) The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide. *Faseb J* 22: 3992–4004.
- Corti A, Mannarino C, Mazza R, Angelone T, Longhi R, et al. (2004) Chromogranin A N-terminal fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiostatsins on the isolated working frog heart. *Gen Comp Endocrinol* 136: 217–224.
- Tota B, Mazza R, Angelone T, Nullans G, Metz-Boutigue MH, et al. (2003) Peptides from the N-terminal domain of chromogranin A (vasostatins) exert negative inotropic effects in the isolated frog heart. *Regul Pept* 114: 123–130.
- Blois A, Srebro B, Mandala M, Corti A, Helle KB, et al. (2006) The chromogranin A peptide vasostatin-1 inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. *Regul Pept* 135: 78–84.
- Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, et al. (2004) Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. *Faseb J* 18: 554–556.
- Gasparri A, Sidoli A, Sanchez LP, Longhi R, Siccardi AG, et al. (1997) Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain. *J Biol Chem* 272: 20835–20843.
- Amato A, Corti A, Serio R, Mule F (2005) Inhibitory influence of chromogranin A N-terminal fragment (vasostatin-1) on the spontaneous contractions of rat proximal colon. *Regul Pept* 130: 42–47.
- Ghia JE, Pradaud I, Crenner F, Metz-Boutigue MH, Aunis D, et al. (2005) Effect of acetic acid or trypsin application on rat colonic motility in vitro and modulation by two synthetic fragments of chromogranin A. *Regul Pept* 124: 27–35.
- Briolat J, Wu SD, Mahata SK, Gonthier B, Bagnard D, et al. (2005) New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. *Cell Mol Life Sci* 62: 377–385.
- Lugardon K, Raffiner R, Goumon Y, Corti A, Delmas A, et al. (2000) Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. *J Biol Chem* 275: 10745–10753.
- Metz-Boutigue MH, Goumon Y, Lugardon K, Strub JM, Aunis D (1998) Antibacterial peptides are present in chromaffin cell secretory granules. *Cell Mol Neurobiol* 18: 249–266.
- Taupenot L, Harper KL, O'Connor DT (2003) The chromogranin-secretogranin family. *N Engl J Med* 348: 1134–1149.
- Zhang K, Rao F, Wen G, Salem RM, Vaingankar S, et al. (2006) Catecholamine storage vesicles and the metabolic syndrome: The role of the chromogranin A fragment pancreastatin. *Diabetes Obes Metab* 8: 621–633.
- Goumon Y, Strub JM, Moniatte M, Nullans G, Poteur L, et al. (1996) The C-terminal bisphosphorylated proenkephalin-A-(209-237)-peptide from adrenal medullary chromaffin granules possesses antibacterial activity. *Eur J Biochem* 235: 516–525.
- Kieffer AE, Goumon Y, Ruh O, Chasserot-Golaz S, Nullans G, et al. (2003) The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities. *Faseb J* 17: 776–778.
- Lugardon K, Chasserot-Golaz S, Kieffer AE, Maget-Dana R, Nullans G, et al. (2001) Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47–66)-derived peptide. *J Biol Chem* 276: 35875–35882.
- Strub JM, Garcia-Sablone P, Lonning K, Taupenot L, Hubert P, et al. (1995) Processing of chromogranin B in bovine adrenal medulla. Identification of secretolytin, the endogenous C-terminal fragment of residues 614–626 with antibacterial activity. *Eur J Biochem* 229: 356–368.
- Sternberg EM (2006) Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. *Nat Rev Immunol* 6: 318–328.
- Genestier AL, Michallet MC, Prevost G, Bellot G, Chalabreysse L, et al. (2005) *Staphylococcus aureus* Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. *J Clin Invest* 115: 3117–3127.

Statistical analysis

Group data are presented as mean \pm SD (as specified in the text and figure legends). Student's t test was used to determine the significance of data (*), $p < 0.05$.

Supporting Information

Figure S1

Found at: doi:10.1371/journal.pone.0004501.s001 (0.30 MB XLS)

Figure S2

Found at: doi:10.1371/journal.pone.0004501.s002 (0.41 MB PDF)

Acknowledgments

We are grateful to Raymonde Girardot (EA 3432, Faculté de Médecine, Strasbourg) for expert technical assistance in neutrophils preparation and flow cytometry measurements. We thank Bernard Guérold (Inserm U575, Strasbourg) for his excellent technical expertise in peptide synthesis.

Author Contributions

Conceived and designed the experiments: DAC JDB AVD FS DA GP MHMB. Performed the experiments: DZ BJL JV SCG FD. Analyzed the data: DZ PS BJL DAC JV JDB SCG KH GP MHMB. Contributed reagents/materials/analysis tools: PS DAC JFC JDB DA MHMB. Wrote the paper: DZ BJL JFC KH GP MHMB.

28. Joubert O, Viero G, Keller D, Martinez E, Colin DA, et al. (2006) Engineered covalent leucotoxin heterodimers form functional pores: insights into S-F interactions. *Biochem J* 396: 381–389.
29. Jean-Francois F, Castano S, Desbat B, Odaert B, Roux M, et al. (2008) Aggregation of cateslytin beta-sheets on negatively charged lipids promotes rigid membrane domains. A new mode of action for antimicrobial peptides? *Biochemistry* 47: 6394–6402.
30. Jean-Francois F, Elezgaray J, Berson P, Vacher P, Dufourc EJ (2008) Pore formation induced by an antimicrobial peptide: electrostatic effects. *Biophys J*.
31. Jean-Francois F, Khemtoumian L, Odaert B, Castano S, Grelard A, et al. (2007) Variability in secondary structure of the antimicrobial peptide Cateslytin in powder, solution, DPC micelles and at the air-water interface. *Eur Biophys J* 36: 1019–1027.
32. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, et al. (1997) Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. *J Clin Invest* 100: 1623–1633.
33. Balsinde J, Balboa MA (2005) Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells. *Cell Signal* 17: 1052–1062.
34. Lohr C, Deitmer JW (2006) Calcium signaling in invertebrate glial cells. *Glia* 54: 642–649.
35. Parekh AB, Putney JW Jr. (2005) Store-operated calcium channels. *Physiol Rev* 85: 757–810.
36. Smani T, Zakharov SI, Csutora P, Leno E, Trepakova ES, et al. (2004) A novel mechanism for the store-operated calcium influx pathway. *Nat Cell Biol* 6: 113–120.
37. Smani T, Zakharov SI, Leno E, Csutora P, Trepakova ES, et al. (2003) Ca²⁺-independent phospholipase A2 is a novel determinant of store-operated Ca²⁺ entry. *J Biol Chem* 278: 11909–11915.
38. Itagaki K, Kannan KB, Livingston DH, Deitch EA, Fekete Z, et al. (2002) Store-operated calcium entry in human neutrophils reflects multiple contributions from independently regulated pathways. *J Immunol* 168: 4063–4069.
39. Rhoads AR, Friedberg F (1997) Sequence motifs for calmodulin recognition. *Faseb J* 11: 331–340.
40. Yoo SH (1992) Identification of the Ca(2+)-dependent calmodulin-binding region of chromogranin A. *Biochemistry* 31: 6134–6140.
41. Jenkins CM, Wolf MJ, Mancuso DJ, Gross RW (2001) Identification of the calmodulin-binding domain of recombinant calcium-independent phospholipase A2beta. implications for structure and function. *J Biol Chem* 276: 7129–7135.
42. Bolotina VM (2004) Store-operated channels: diversity and activation mechanisms. *Sci STKE* 2004: pe34.
43. Bolotina VM, Csutora P (2005) CIF and other mysteries of the store-operated Ca²⁺-entry pathway. *Trends Biochem Sci* 30: 378–387.
44. Csutora P, Zarayskiy V, Peter K, Monje F, Smani T, et al. (2006) Activation mechanism for CRAC current and store-operated Ca²⁺ entry: calcium influx factor and Ca²⁺-independent phospholipase A2beta-mediated pathway. *J Biol Chem* 281: 34926–34935.
45. Mookherjee N, Hancock RE (2007) Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. *Cell Mol Life Sci* 64: 922–933.
46. Radek K, Gallo R (2007) Antimicrobial peptides: natural effectors of the innate immune system. *Semin Immunopathol* 29: 27–43.
47. Angeletti RH, Aardal S, Serck-Hanssen G, Gee P, Helle KB (1994) Vaso-inhibitory activity of synthetic peptides from the amino terminus of chromogranin A. *Acta Physiol Scand* 152: 11–19.
48. Russell J, Gee P, Liu SM, Angeletti RH (1994) Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. *Endocrinology* 135: 337–342.
49. Henriques ST, Melo MN, Castanho MA (2006) Cell-penetrating peptides and antimicrobial peptides: how different are they? *Biochem J* 399: 1–7.
50. Lewis RS (2007) The molecular choreography of a store-operated calcium channel. *Nature* 446: 284–287.
51. Randriamampita C, Tsien RY (1993) Emptying of intracellular Ca²⁺ stores releases a novel small messenger that stimulates Ca²⁺ influx. *Nature* 364: 809–814.
52. Lominadze G, Powell DW, Luerman GC, Link AJ, Ward RA, et al. (2005) Proteomic analysis of human neutrophil granules. *Mol Cell Proteomics* 4: 1503–1521.
53. Wong SH, Francis N, Chahal H, Raza K, Salmon M, et al. (2009) Lactoferrin is a survival factor for neutrophils in rheumatoid synovial fluid. *Rheumatology (Oxford)* 48: 39–44.
54. de la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ (2008) Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. *J Immunol* 180: 6868–6876.
55. Oseas R, Yang HH, Baehner RL, Boxer LA (1981) Lactoferrin: a promoter of polymorphonuclear leukocyte adhesiveness. *Blood* 57: 939–945.
56. Legrand D, Ellass E, Carpentier M, Mazurier J (2005) Lactoferrin: a modulator of immune and inflammatory responses. *Cell Mol Life Sci* 62: 2549–2559.
57. Laible NJ, Germaine GR (1985) Bactericidal activity of human lysozyme, muramidase-inactive lysozyme, and cationic polypeptides against *Streptococcus sanguis* and *Streptococcus faecalis*: inhibition by chitin oligosaccharides. *Infect Immun* 48: 720–728.
58. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. *J Biol Chem* 268: 10425–10432.
59. Triebel S, Blaser J, Reinke H, Tschesche H (1992) A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. *FEBS Lett* 314: 386–388.
60. Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, et al. (2006) Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. *Am J Pathol* 169: 2245–2253.
61. Andersson KB, Sletten K, Berntzen HB, Fagerhol MK, Dale I, et al. (1988) Leukocyte L1 protein and the cystic fibrosis antigen. *Nature* 332: 688.
62. Koike T, Kondo K, Makita T, Kajiyama K, Yoshida T, et al. (1998) Intracellular localization of migration inhibitory factor-related protein (MRP) and detection of cell surface MRP binding sites on human leukemia cell lines. *J Biochem* 123: 1079–1087.
63. Odink K, Cerletti N, Bruggen J, Clerc RG, Tarcsay L, et al. (1987) Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. *Nature* 330: 80–82.
64. Nacken W, Roth J, Sorg C, Kerkhoff C (2003) S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. *Microsc Res Tech* 60: 569–580.
65. Roth J, Vogl T, Sorg C, Sunderkotter C (2003) Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. *Trends Immunol* 24: 155–158.
66. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, et al. (2006) The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. *Arthritis Res Ther* 8: R69.
67. Kang Y, Taldone T, Clement CC, Fewell SW, Aguirre J, et al. (2008) Design of a fluorescence polarization assay platform for the study of human Hsp70. *Bioorg Med Chem Lett* 18: 3749–3751.
68. Lasunskaja EB, Fridlianskaia II, Guzhova IV, Bozhkov VM, Margulis BA (1997) Accumulation of major stress protein 70kDa protects myeloid and lymphoid cells from death by apoptosis. *Apoptosis* 2: 156–163.
69. Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH (2003) Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. *Nat Immunol* 4: 965–973.
70. Cheung NS, Karlsson P, Wang JX, Bienert M, Oehme P, et al. (1994) Functional studies with substance P analogues: effects of N-terminal, C-terminal, and C-terminus-extended analogues of substance P on nicotine-induced secretion and desensitization in cultured bovine adrenal chromaffin cells. *J Neurochem* 62: 2246–2253.
71. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, et al. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. *Pharmacol Rev* 52: 269–324.
72. Harfi I, Corazza F, D'Hondt S, Sariban E (2005) Differential calcium regulation of proinflammatory activities in human neutrophils exposed to the neuropeptide pituitary adenylate cyclase-activating protein. *J Immunol* 175: 4091–4102.
73. Morita K, Sakakibara A, Kitayama S, Kumagai K, Tanne K, et al. (2002) Pituitary adenylate cyclase-activating polypeptide induces a sustained increase in intracellular free Ca(2+) concentration and catechol amine release by activating Ca(2+) influx via receptor-stimulated Ca(2+) entry, independent of store-operated Ca(2+) channels, and voltage-dependent Ca(2+) channels in bovine adrenal medullary chromaffin cells. *J Pharmacol Exp Ther* 302: 972–982.
74. Gevaert K, Vandekerckhove J (2000) Protein identification methods in proteomics. *Electrophoresis* 21: 1145–1154.
75. Colin DA, Mazurier I, Sire S, Finck-Barbancon V (1994) Interaction of the two components of leukocidin from *Staphylococcus aureus* with human polymorphonuclear leukocyte membranes: sequential binding and subsequent activation. *Infect Immun* 62: 3184–3188.
76. Meunier O, Falkenrodt A, Monteil H, Colin DA (1995) Application of flow cytometry in toxinology: pathophysiology of human polymorphonuclear leukocytes damaged by a pore-forming toxin from *Staphylococcus aureus*. *Cytometry* 21: 241–247.
77. Baba Moussa L, Werner S, Colin DA, Mourey L, Pedelacq JD, et al. (1999) Decoupling the Ca(2+)-activation from the pore-forming function of the bi-component Panton-Valentine leucocidin in human PMNs. *FEBS Lett* 461: 280–286.
78. Jonsson U, Fagerstam L, Ivarsson B, Johnsson B, Karlsson R, et al. (1991) Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. *Biotechniques* 11: 620–627.
79. Muller A, Glattard E, Taleb O, Kemmel V, Laux A, et al. (2008) Endogenous morphine in SH-SY5Y cells and the mouse cerebellum. *PLoS ONE* 3: e1641.
80. Elias JE, Gygi SP (2007) Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. *Nat Methods* 4: 207–214.